Contineum Therapeutics, Inc. CTNM
12.56
0.07
0.56%
as of 25 Sep
- Market cap
- $469.9M
- P/E
- 0.0×
Follow CTNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(30.40%) | (26.13%) | (26.88%) | (28.01%) | |
| (29.19%) | (24.51%) | (25.43%) | (26.57%) | ||
ROIC |
0.00% | 0.00% | (1,125.32%) | (1,334.41%) | |
Return on Tangible Assets |
(33.09%) | (23.16%) | (23.63%) | (24.29%) | |
Free Cash Flow per Share |
(1.88) | (2.01) | (1.54) | (1.43) | |
Free Cash Flow |
(52.83) | (55.54) | (57.66) | (53.46) | |
Capital Expenditures |
(0.35) | (0.23) | (0.50) | (0.46) | |
Piotroski F-Score |
3.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(14.46%) | (10.56%) | (11.52%) | (11.13%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.92 | 0.98 | 0.92 | |
Depreciation/Fixed assets |
0.36 | 0.39 | 0.31 | 0.41 | |
Capex/Depreciation |
(1.13) | (0.72) | (1.51) | (1.20) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.87) | (2.00) | (1.53) | (1.41) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates